| (Values in U.S. Thousands) | Dec, 2014 | Dec, 2013 | Dec, 2012 | Feb, 2026 | Feb, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 9,800 | -4,300 | -3,060 | 0 | 0 |
| Net Income Growth | +327.91% | -40.52% | unch | unch | unch |
Cynapsus Therapeutic (CYNAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cynapsus Therapeutics, Inc. is a specialty pharmaceutical company engaged in developing a drug used to treat the symptoms of Parkinson's disease. The Company's drug candidate, APL-130277, is a reformulation of apomorphine, which is approved in an injection formulation to rescue patients from `off` episodes. Cynapsus Therapeutics Inc. is headquartered in Toronto, Canada.